Trial Profile
A Pilot Study to Investigate Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2021
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Therapeutic Use
- Acronyms STAR
- 24 Dec 2020 Status changed from recruiting to completed.
- 17 Jun 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 28 Sep 2019 Planned End Date changed from 18 Jul 2020 to 31 Dec 2020.